Janssen is pushing hard for new approvals for the Genmab-developed cancer drug Darzalex which is being tested in a range of phase III studies. This year, the biotech expects data from a trial that could clear the product for front-line use against multiple myeloma and double the potential market, says its CEO.
BY LOUISE WENDT JENSEN Offentliggjort 29.03.17 kl. 15:02
Log ind for at læse artikler
Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.
Lundbeckfonden Ventures’ portfolio company Bonesupport has listed on the Swedish stock market and raised SEK 500 million (about USD 57 million). The IPO puts a period to a busy half year, where two other companies have been sold. New investments are coming up, says managing partner Mette Kirstine Agger.
The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.
The world’s largest hearing device dealer, Amplifon, expresses concern over the entry into the retail market of manufacturers such as William Demant. GN Resound, on the other hand, receives praise and is expected to form even closer ties to its Italian collaborator.
With an overwhelming majority, an independent advisory committee under the US drug agency FDA has found that Novo Nordisk’s Leader study provides substantial evidence of cardiovascular risk reduction in treatment with Victoza. The result opens up the opportunity for including the data on the product’s US label.